Viatris stock slides 24% as analysts say sale of biosimilars to Indian partner removes key growth driver
February 28, 2022 at 14:15 PM EST
Viatris Inc. said Monday it has agreed to combine its biosimilars portfolio with privately held Indian company Biocon Biologics Ltd. for up to $3.335 billion, as part of a broader overhaul of its business following a strategic review.
